CRSP vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FDMT Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to 4D Molecular Therapeutics, Inc. Common Stock (FDMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | FDMT Revenue | CRSP Op. Margin | FDMT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -5087.8% | N/A | CRSP |
| FY2019 | $290M | $10M | 16.1% | -729.4% | CRSP |
| FY2020 | $0M | $10M | -49295.5% | -424.0% | FDMT |
| FY2021 | $910M | $20M | 40.8% | -395.5% | CRSP |
| FY2022 | $0M | $0M | -56190.4% | -3516.5% | FDMT |
| FY2023 | $370M | $20M | -60.0% | -544.6% | CRSP |
| FY2024 | $40M | $0M | -1250.4% | -507678.4% | CRSP |
| FY2025 | $0M | $90M | -18933.6% | -187.2% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $669.3M | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -2058.6% | -222.7% | Higher Margin | FDMT |
| Net Profit Margin Profitability | 0.0% | -208.6% | Higher Margin | CRSP |
| Return on Equity (ROE) Capital Efficiency | -25.6% | -56.7% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | FDMT |